Last reviewed · How we verify
iv sildenafil
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis to treat erectile dysfunction.
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis to treat erectile dysfunction. Used for Erectile dysfunction.
At a glance
| Generic name | iv sildenafil |
|---|---|
| Also known as | revatio |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | PDE5 inhibitor |
| Target | PDE5 |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
PDE5 is an enzyme found in the smooth muscle of the corpus cavernosum of the penis. By inhibiting PDE5, sildenafil increases the levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation and increased blood flow.
Approved indications
- Erectile dysfunction
Common side effects
- Headache
- Flushing
- Dyspepsia
- Back pain
- Muscle pain
- Nasal congestion
- Dizziness
- Vision changes
- Abnormal vision
- Abnormal dreams
Key clinical trials
- Safety of Sildenafil in Premature Infants (PHASE2)
- Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy (PHASE2)
- Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia (PHASE2)
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (PHASE4)
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (PHASE4)
- Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military (PHASE2)
- A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis (PHASE1)
- A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iv sildenafil CI brief — competitive landscape report
- iv sildenafil updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI